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ABSTRACT 
 
Background:  Heart failure has a high mortality rate with 20% dying within the first 
year after diagnosis. The gold standard of treatment has been cardiac transplant 
however the shortage of donors continues to be a problem. Left ventricular assist 
devices (LVAD) have been bridging patients to transplantation, but they come 
with many complications. The HeartWare HVAD system is a promising new 
smaller LVAD that will hopefully improve the survival of heart failure patients 
awaiting transplant. The evidence of the clinical trials in this review was 
evaluated using the GRADE system. 
 
Method:  An exhaustive search of available medical literature was conducted 
using Medline, CINHAL, and Evidence-Based Medicine Reviews Multifile. The 
terms used in the search included the words, “Heartware, HVAD, and transplant” 
with limits set for human subjects, the English language, and articles published 
since the year 2000. After one clinical trial was found the author of that trial was 
searched to find the second article then included in this review. 
 
Results:  Two studies were reviewed in this systematic review. Both found that 
the HeartWare device was effective and safe in bridging end-stage heart failure 
patients to transplantation. The first study showed survival was 91% at 180 days 
and 86% at one year and the second study showed survival was 90% at 180 
days, 84% at one year, and 79% at two years.  
 
Conclusion:  The HeartWare HVAD system is effective and safe in bridging end-
stage heart failure patients to transplantation. 
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INTRODUCTION 
Background 
 According to the Centers for Disease Control, heart failure in the United 
States affects approximately 5.8 million people (Lloyd-Jones et al., 2010). The 
average American has a one in five lifetime risk of developing heart failure after 
the age of forty (Lloyd-Jones et al., 2010). Once diagnosed with heart failure, one 
in five people will die from the disease in less than one year (Lloyd-Jones et al., 
2010). Heart failure is an epidemic affecting the worldwide population and the 
number of people being diagnosed with the disease is continuing to climb 
(Strueber et al., 2011). With this anticipated steady rise of people diagnosed with 
heart failure, it is imperative that current treatments are improved and new 
treatments are developed. 
 Heart failure is failure of the heart muscle to effectively pump blood to the 
vital organs of the body, which can lead to multiple organ failure, and eventually 
death. The two different types of heart failure are diastolic and systolic and both 
types are caused by dysfunctional ventricles of the heart (Colucci, 2009). 
Symptoms of heart failure include shortness of breath on exertion, dyspnea while 
laying down, edema in the legs and feet, and fatigue (Colucci, 2009). The most 
common causes of heart failure in the U.S. include, but are not limited to, 
coronary artery disease, hypertension, and diabetes (Lloyd-Jones et al., 2010).  
 Treatment for heart failure as the disease progresses can be thought of as 
a continuum. Often treatment is determined by the New York Heart Association 
(NYHA) functional classification system. The NYHA classification categorizes 
patients with heart failure into four classes based on how many physical 
limitations a patient has from their disease. A heart failure patient with no 
physical limitations is a class I and a heart failure patient with severe physical 
limitations is a class IV (Colucci & Pina, 2011). Goals for heart failure treatment 
include symptom control, stopping or reversing myocardial dysfunction, and 
reducing mortality (Colucci, 2009). Initial treatment, if applicable, is aimed at 
correcting the underlying cause of the heart failure, such as hypertension, 
coronary artery disease, and/or valvular disease. Patients should then be treated 
with lifestyle modifications like smoking cessation, sodium restriction, and weight 
reduction if overweight (Colucci, 2009). The most common pharmacologic 
therapies to be started include in order: loop diuretics for fluid overload control, 
ACE inhibitors or angiotensin II receptor blockers (ARBs) for hemodynamic 
benefit, and beta blockers that are cardio-protective (Colucci, 2009).   
 Unfortunately, there are some patients who do not respond to these 
pharmacologic therapies. These patients have refractory heart failure and they 
require different treatments due to the severity of their illness.  Therapy is guided 
towards use of intravenous inotropes and vasodilators, which require these 
patients to be hospitalized (Colcucci, 2010). Inotropes and vasodilators will help 
relieve symptoms and improve hemodynamics in these patients. Another 
treatment is ultrafiltration which moves fluid from the interstitial compartment into 
the vascular space and then from the body (Colcucci, 2010). If still refractory to 
treatment then cardiac transplantation and/or mechanical cardiac support should 
be considered. 
 Cardiac transplantation is reserved for those patients with end-stage heart 
failure or NYHA class III or IV. Transplantation can improve survival and the 
quality of life for many of them. In one study, survival after transplantation was 
85% after one year and 79% after three years (Colcucci, 2010). Unfortunately, 
there is a higher need for organs than there are donors by a factor of 10 and 
thus, many patients die awaiting transplantation (Colucci & Pina, 2011).   
 Mechanical assist devices are designed to add support to failing left 
and/or right ventricles of the heart. These ventricular assist devices have even 
been shown to improve contractile properties of the heart, reverse the down-
regulation of beta receptors in the heart, and correct anatomical abnormalities of 
the heart. There are many different types of mechanical support device that are 
designed for either short-term use as in a bridge to transplant, or for long-term 
use as in destination therapy when a patient is ineligible for transplantation 
(Jeevanandam & Eisen, 2010).  
 The short-term devices consist of paracorporeal ventricular assist devices 
that are located outside the body such as the Thoratec Ventricular Assist Device 
and the Abiomed AB 500 (Jeevanandam & Eisen, 2010).  Both of these devices 
can be configured to assist the left and/or right ventricles and are FDA approved.  
There are many complications with these two devices that involve bleeding, 
infection, and thromboembolism and thus they should only be used as temporary 
solutions (Jeevanandam & Eisen, 2010). 
 The long-term devices can be used for either bridge to transplant or as 
destination therapy alone.  The three major FDA approved left ventricular assist 
devices (LVAD) used today, are the WorldHeart Novacor and the Thoractec 
HeartMate XVE, and HeartMate II (Jeevanandam & Eisen, 2010). The HeartMate 
XVE and the Novacor pumps produce a pulsatile flow of blood mimicking the 
heart, whereas the HeartMate II pump produces a continuous axial flow 
(Jeevanandam & Eisen, 2010). All of these devices are implanted internally 
below the diaphragm and are connected to the left ventricle and aorta with a 
pump mechanism in between. To place these devices requires a sternotomy and 
creation of a pump pocket in the abdominal cavity.  As with the short-term 
devices these devices also have complications with bleeding, infection, and 
thromboembolism (Jeevanandam & Eisen, 2010). 
 The newest LVAD systems include the HeartWare HVAD, Ventrocor 
VentrAssist LVAD, and the Terrumo Duraheart which are all currently involved in 
clinical trials in the U.S. and thus, are not currently FDA approved. These devices 
have a different mechanism of action than the other LVADs and provide a 
centrifugal continuous flow.  These devices are also more energy efficient, less 
prone to cause thromboembolism, easier and faster to insert resulting in less 
time on the bypass machine, and are more durable possibly as long lasting as 10 
years (Jeevanandam & Eisen, 2010).  
 In January 2009, the HeartWare HVAD system was approved in Europe 
(CE Mark authorized) and has since started undergoing clinical trials in the U.S. 
(LaRose, Tamez, Ashenuga, & Reyes, 2010). This system is very promising as a 
device for a bridge to transplant and even as a destination therapy for those 
ineligible for transplantation. The system is very small, weighing only 145 grams, 
and is implanted in the pericardial space, eliminating the need for a pump pocket 
in the abdominal cavity which would be a second surgical incision (LaRose et al., 
2010). It has a broad-based impeller that is suspended in between the two 
housing pieces. This is unique to this product since the impeller does not come 
into contact with either of the housing pieces, eliminating wear on the device 
(LaRose et al., 2010).  The impeller is the only moving part of the device and is 
powered by electromagnetic force. The device is powered by either an AC/DC 
power source or lithium-ion batteries that will last up to 12 hours (LaRose et al., 
2010). It also has a touch screen tablet PC that shows how the system in 
operating and monitors battery life. The batteries and tablet PC maybe worn on a 
belt or carried over the patient’s shoulder allowing mobility (LaRose et al., 2010).  
This system has the capacity to be the next best LVAD on the market due to the 
ease of implantation, small size, durability, longevity of cardiac support, and the 
ease of mobility for the patient.  
 
Purpose of the Study 
 The purpose of this paper is to perform a systematic review of the 
literature on the use of the HeartWare Ventricular Assist System in bridging heart 
failure patients to transplantation. The body of evidence will be evaluated using 
the Grading of Recommendations Assessment, Development and Evaluation 
(GRADE) tool developed by the GRADE Working Group (Guyatt et al., 2008). 
METHOD 
 
An extensive literature search was conducted using Medline, CINHAL, 
and Evidence-Based Medicine Reviews Multifile. These databases were 
accessed through the Pacific University Library system. The keywords searched, 
individually and in combination, included: “HeartWare, HVAD, and transplant”. 
The search was limited to human subjects, the English language, and articles 
published since the year 2000. Only the articles that included “HeartWare, 
HVAD, and transplant” in combination were included. This resulted in four articles 
and, of these, only one was a clinical trial which was included in this systematic 
review. To find more articles, the first clinical trials’ primary author G.M. 
Wieselthaler was searched which resulted in 19 articles. Of these articles only 
two were clinical trials on the HeartWare Ventricular Assist System, one was the 
first clinical trial found and the other article was new and is included in the review. 
 
RESULTS  
The first clinical trial reviewed titled the “Initial Clinical Experience With a 
Novel Left Ventricular Assist Device With a Magnetically Levitated Rotor in a 
Multi-Institutional Trial” was a prospective, non-randomized, single-arm clinical 
trial for the HeartWare HVAD system (Wieselthaler, O’Driscoll, Jansz, Khaghani, 
& Strueber 2010). The goal of the study was to look at the efficacy of the HVAD 
system as a bridge to cardiac transplantation for patients with refractory end-
stage heart failure. There were 23 participates that were enrolled during the 
period between March 2006 and November 2007 at five centers located in 
Europe and Australia (Appendix A. Table 1). At the time of enrollment, all of the 
participants were in NYHA class IV heart failure and were receiving intravenous 
inotropic therapy (Appendix B. Table 2). The primary end point of the study was 
survival to cardiac transplantation or to 180 days on the pump. If the patients 
remained on the pump longer than 180 days then they were followed up to one 
year. All of the pumps were implanted using the same procedure, through a 
standard sternotomy and patients were put on a normothermic cardiopulmonary 
bypass machine. Post-operatively the patients were anti-coagulated with 
unfractionated heparin which was later replaced with warfarin to achieve an INR 
of 2.5-3.0. (Wieselthaler et al., 2010) 
The results of this first study showed that survival was 91% at 180 days 
and 86% at one year (Wieselthaler et al., 2010). The mean duration of support of 
the device was 167 ± 143 days. After one year from the start of the study, five 
patients received a cardiac transplant, 14 were still on the HVAD device, one 
patient was weaned off the device, two patients died from multi-organ failure 
caused by septicemia, and another patient died of an intracranial hemorrhage. 
The adverse events after one year from the start of the study included, infections 
(not related to the device), bleeding, cardiac arrhythmias, hemolysis, pleural 
effusions, pneumonia, device replacement, renal dysfunction, right heart failure, 
and cerebrovascular accidents. Thrombus formation occurred inside the pump 
leading to replacement in six of the first 13 implants. This was suspected to be 
due to a manufacturing defect which was later fixed and no other issues have 
occurred since. The mean time on the cardiopulmonary bypass machine was 67 
minutes and there were no complications with the implant procedures. There 
were 21 patients that were able to be discharged home and only nine post-
implant re-admissions to the hospital for complications. Prior to the study year, 
this same group of patients had been admitted to the hospital for heart failure 
treatment 2.7 ± 3 times per patient-year (Wieselthaler et al., 2010). The authors 
of the study state that this study has comparable results in initial clinical trials of 
other left ventricular assist devices, which demonstrates efficacy of the device. 
They also talk about how this is an important device in the context of support to 
heart failure patients awaiting transplantation in countries where the wait time 
can be as long as 269 days (Wieselthaler et al., 2010). Their conclusion was that 
the HVAD system is effective and safe as a bridge to transplantation and is 
comparable with other left ventricular assist devices. The study also showed that 
the pump provided great hemodynamic support and that myocardial recovery is 
possible when the device is used for at least one year (Wieselthaler et al., 2010). 
The second clinical trial included in this review entitled, “Multicenter 
Evaluation of an Intrapericardial Left Ventricular Assist System” was the same 
type of study, had the same goals, took place in the same locations, and patients 
underwent the same implant procedure as in the first study (Strueber et al., 
2011). The trial enrolled 50 NYHA class IV participants between March 2006 and 
December 2008 (Appendix A. Table 1). All of the patients enrolled were receiving 
intravenous inotropic therapy (Appendix B. Table 2). The patients were followed 
up until June 2009 for adverse events or until they reached the end points. The 
primary end points were survival to cardiac transplant, survival to 180 days, or 
cardiac recovery enough to explant the pump. The study was done in compliance 
with the U.S. Food and Drug Administration guidelines. Anti-coagulation therapy 
was initiated post-operatively with IV heparin. Patients were then transitioned to 
warfarin (achieved an INR of 2.0-3.0) and aspirin or clopidogrel. After 
implantation, patients were given rehabilitative care and education about the 
device (Strueber et al., 2011). 
The survival rates to transplantation, cardiac recovery with device explant, 
or ongoing cardiac support with the device was 90% at 180 days, 84% at one 
year, and 79% at two years (Strueber et al., 2011). These results were compared 
with the Seattle Heart Failure Model (SHFM) which estimated survival of the 
study group with only medical therapy. The SHFM estimated the cohort survival 
to180 days at 73 ± 3%, 58 ± 4% at one year, and 40 ± 4% at two years. The 
mean duration on the device was 348 days. As of May 2010, 20 patients had 
cardiac transplants, four patients had cardiac recovery and the device was 
explanted, and 17 were still supported on the device. Nine patients died while on 
the support device between 13-515 days on the device. Causes of these deaths 
include sepsis, multi-organ failure, and hemorrhagic stroke. Other adverse 
events included infection at the driveline exit site, sepsis, bleeding, ventricular 
arrhythmias, ischemic and hemorrhagic stroke, transient ischemic attacks, device 
replacement, and right heart failure requiring right ventricular assist devices. 
Forty-seven patients were able to be discharged home and there were 53 re-
admissions to the hospital. This was a 74% reduction of re-admission to the 
hospital compared with the average re-admission rate of the cohort a year prior 
to the study (Strueber et al., 2011). The authors of this study concluded that the 
HVAD system can effectively and safely bridge end-stage heart failure patients to 
transplantation. They commented that the two-year survival rate on the HVAD 
system was similar to that of a cardiac transplant, which could open the doors to 
using this device as a destination therapy. They also stated that the patients on 
the device had improvements in circulation and had low adverse events. The size 
and location of the device was of benefit as well, eliminating the need for entry 
into the abdominal cavity for placement of a pump pocket. Less time on the 
cardiopulmonary bypass machine was needed as a result of the size and location 
of the device. 
DISCUSSION 
Today, transplantation continues to be the best option for the treatment 
and survival of end-stage heart failure. However, there is a 10-fold difference in 
the number of patients needing a heart transplant and those who will actually 
receive one before it is too late (Lloyd-Jones et al., 2010). The need for improved 
ventricular assist devices or other treatment strategies for end-stage heart failure 
has never been more apparent.   
The HeartWare HVAD system is a promising ventricular assist device for 
the support of patients to transplantation as shown by the two clinical trials in this 
review. The first clinical trial reviewed entitled, “Initial Clinical Experience With a 
Novel Left Ventricular Assist Device With a Magnetically Levitated Rotor in a 
Multi-Institutional Trial” was a prospective, non-randomized, single-arm clinical 
trial (Wieselthaler et al., 2010). This means that the trial is an observational study 
and, more specifically, a prospective cohort study. Cohort studies follow patients 
who receive a particular treatment or intervention and compare them with a 
similar population of patients that did not receive the intervention. In this case, 
this study did not directly compare the group of patients that received the HVAD 
with a group of patients that did not receive the HVAD device, making it a single 
arm study. The study was also prospective meaning the patients were involved in 
the study prior to the intervention. The outcomes of this first study are very 
promising showing that 91% of the patients had survived on the device until 180 
days and that 86% had survived on the device for one year (Wieselthaler et al., 
2010). Some of those patients have received cardiac transplants. This study also 
concluded that the patients had fewer re-admissions to the hospital, even though 
the data that shows this is confusing to interpret. This is just one of the multiple 
limitations of the study.  Another limitation was the small number of patients 
involved and the study design. The study would have been of higher quality if 
there were two groups of patients randomized to two different interventions 
instead of one group all receiving the same intervention. By not comparing this 
intervention with either medical therapy alone or another LVAD device the 
outcomes of the study stand alone and do not show how survival is effected with 
the HVAD device as a bridge to transplant. A major limitation to the study was 
the fact that G.M. Wieselthaler (one of the study’s authors) is a member of the 
Medical Advisory Board of HeartWare Inc. and his hospital receives grants from 
the company (Wieselthaler et al., 2010). This means that there is a potential for 
bias in how the study was conducted, who was involved, and how the data was 
reported in the study. 
The second clinical trial reviewed entitled, “Multicenter Evaluation of an 
Intrapericardial Left Ventricular Assist System” was also a non-randomized, 
single arm, prospective cohort study (Strueber et al., 2011). The outcomes of this 
trial were very similar to those of the first study, showing that there was a 90% 
survival rate to 180 days, 84% survival rate at one year, and 79% survival rate at 
two years on the device (Strueber et al., 2011). In this trial the results were 
compared with the Seattle Heart Failure Model (SHFM) which estimated the 
survival of the study group during the same time with only medical therapy. The 
SHFM estimated the cohort survival to180 days was approximately 73%, 58% at 
one year, and 40% at two years (Strueber et al., 2011). If these estimates are 
correct then this study does show survival was improved with the use of the 
HVAD device. However these estimates are theory and are not as powerful as a 
randomized two arm control trial would be. This would be considered a limitation 
to the study. Another limitation includes the study design not being randomized 
or blinded. The study does state, that, after the first trial it would be unethical to 
randomize patients to the HVAD device or continued medical support since there 
was already data showing that survival was improved with the HVAD device. 
Even though this study had more patients than the first, it was still a very small 
group of patients. Other limitations that were stated include patient selection bias 
and variability in how the patients were cared for while in the hospital (Strueber et 
al., 2011). A large limitation to this study is that fact that HeartWare Inc., the 
manufacturer of the system, was the financial sponsor of the study (Strueber et 
al., 2011). Unlike the first study, this study does not have a paragraph at the end 
of the paper stating that G.M. Wieselthaler (one of the authors) is a member of 
the Medical Advisory Board of HeartWare Inc. and his hospital receives grants 
from the company. This information was written in very small text font at the 
bottom of the first page. In contrast to the first study, this paper points out that the 
authors M. Strueber, P. Jansz, and A. Khaghani are Principle Investigators to 
HeartWare Inc. (Strueber et al., 2011). Authors M. Strueber is a consultant to 
HeartWare Inc., G. O’Driscoll is a HeartWare advisory board member and W. 
Levy has received research funding from HeartWare Inc. (Strueber et al., 2011). 
It is concerning that every author of this study has a connection to the 
manufacturer of the HeartWare HVAD system, either financially or as an advisor. 
The purpose of this systematic review was to review the literature on the 
efficacy of the HVAD system in bridging end-stage heart failure patients to 
transplant. To evaluate the literature the Grading of Recommendations 
Assessment, Development and Evaluation (GRADE) system was used. It was 
developed by the GRADE Working Group for evaluating the quality of outcomes 
and recommendations of clinical trials (Guyatt et al., 2008). The GRADE system 
is an important tool for helping practitioners evaluate the strength of 
recommendations and whether or not they should implement the 
recommendations into their practice. The GRADE system works by categorizing 
the trials together with the same outcomes. For each outcome the quantity and 
type of clinical studies are factored together to determine a starting grade. The 
high starting grade is awarded to randomized control trials (RCT) and the low 
starting grade is awarded to observational studies. From there the starting grade 
is either increased or decreased based on different factors that affect the quality 
of evidence. At the end of the table all of the outcomes and grades are factored 
together to give one grade of either ‘high, moderate, or low’ quality of evidence 
(Guyatt et al., 2008). From here the recommendations are either categorized into 
‘strong’ or ‘weak’ recommendations based on the quality of evidence and the 
benefits and harms of the intervention (Guyatt et al., 2008). As with many grading 
systems the GRADE system is subject to individual biases of the grader. Yet this 
system claims to be superior to many other systems because it was developed 
by an international group of guideline developers and is used by many world 
renown organizations including the World Health Organization, the American 
College of Physicians, UpToDate, and the Cochrane Collaboration to name a few 
(Guyatt et al., 2008).  
The GRADE table for the clinical trials in this review can be found in the 
appendices (Appendix C. Table 3). The table will be discussed in detail to help 
the reader better understand how the overall grade for the studies was 
determined. The comparison and purpose of this review is the efficacy of the 
HVAD system on bridging end-stage heart failure patients to transplantation. The 
two separate outcomes that were used to compare across the trials was ‘survival 
to transplantation’ and ‘survival 180 days on the device’.  Since both of the 
articles addressed these outcomes they both were placed as observational 
studies in the quantity and type of evidence. Given that both of the studies are 
observational the starting grades for both outcomes are ‘low’ (Guyatt et al., 
2008). Due to the fact that observational studies start out ‘low’ they cannot be 
downgraded any further by the study quality, consistency, directness, precision, 
or publication bias even if they apply. Observational studies can be upgraded if 
there is a large magnitude effect, dose-response, and/or with confounders. 
These clinical trials did have a large magnitude effect and were given a +1 in that 
category. A large magnitude effect means that even though a study may have 
been done with a small population the population represents the type of patients 
that would be seeking the intervention (Guyatt et al., 2008). It also means that 
the same results would be found if the study was re-done with a larger 
population. This determination of a large magnitude of effect was due to the fact 
that most of the patients receiving the intervention were either going to wait in the 
hospital on IV inotropic therapy for a transplant or die waiting. This intervention 
will only be used in patients awaiting transplantation on IV inotropic therapy who 
are in end-stage heart failure (NYHA class IV). The GRADE of evidence for these 
outcomes up to this point are the same and have been upgraded from ‘low’ to 
‘moderate’. This means the overall GRADE of evidence for these two outcomes 
is ‘moderate’. A moderate quality GRADE means that further research is likely to 
have an important impact on the estimate of effect which may change (Guyatt et 
al., 2008). This warrants higher quality trials like randomized control trials with 
other LVAD devices to be done in the future to help strengthen these 
recommendations. Fortunately these types of trials are currently being conducted 
in the United States. The recommendation of using the HVAD system was 
considered ‘strong’ based on the fact that the quality of evidence is moderate and 
the benefits of this intervention outweigh the harms.  
Heart failure is a debilitating disease with a high mortality rate within the 
first year of diagnosis. Cardiac transplantation is really the only treatment at this 
point in time, but with the shortage of donors and long wait time it can be less 
than ideal. Today left ventricular assist devices are starting to help bridge the gap 
between end-stage heart failure and transplantation. As technology continues to 
advance and improve, so does the success of these devices in helping to prolong 
lives. The HeartWare HVAD system is a new type of LVAD that is considerably 
smaller than its competitors and more durable, allowing it to function for a longer 
period of time. In the first clinical trials, the system is shown to have comparable, 
if not better survival rates than other LVADs with end-stage heart failure patients 
awaiting transplantation. The GRADE system showed that these trials have a 
‘moderate’ quality of evidence for use in similar patient populations. In conclusion 
the HeartWare HVAD system has been shown to be safe and effective in 
bridging adult heart failure patients to transplantation. Hopefully, this system will 
soon finish with the U.S. clinical trials so that it can be used to help prolong the 
lives of heart failure patients awaiting transplant. 
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APPENDICES 
 
 
APPENDIX A 
Table 1:  Pre-operative Risk Factors 
 
 Number of patients 
Risk Factor Clinical trial 1 Clinical trial 2 
Coronary angioplasty 6 13 
Previous Sternotomy 5 6 
Pacemaker and/or Implantable 
Cardioverter 
Defibrillator 
16 41 
Moderate-severe right ventricular 
dysfunction 9 19 
Diabetes 4 7 
Inotropic support 23 50 
Previous Myocardial infarction 6 10 
Arrhythmias Not measured 25 
Hypertension Not measured 15 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 APPENDIX B 
Table 2:  Baseline Characteristics of the patients in the clinical trials 
 
Baseline Characteristics Clinical trial 1 Clinical trial 2 
Mean Age (years) 48 48.5 
Gender 20 males, 3 females 43 males, 7 females 
Signed informed consent Meets Meets 
Body Surface Area mean (m²) 1.98 1.9 
Body Mass Index mean (kg/m²) 27.6  25.6 
Heart Failure cause:  
1) idiopathic cardiomyopathy 14 patients 22 patients 
2) Ischemic cardiomyopathy 7 patients 20 patients 
3) Familial or congenital 
cardiomyopathy Not measured 5 patients 
4) Myocarditis 2 patients 3 patients 
Inotropic Support 100% of the patients 100% of the patients 
 
Hemodynamic Parameters 
Left Ventricular Ejection Fraction (%)  20.6 ± 7.4 18.7 ± 5.9 
Left ventricular end-diastolic 
dimension (mm) 68.4 ± 7.5 68.6 ± 8.0 
Cardiac Index (L/min/m²) 1.9 ± 0.5 1.94 ± 0.54 
Pulmonary Capillary Wedge 
Pressure (mm Hg) 23.1 ± 7 23.7 ± 6.5 
Central Venous Pressure (mm Hg) 13 ± 5.7 12.3 ± 5.9 
Mean Systolic Blood Pressure (mm 
Hg) 105 ± 15.8 101.5 ± 13.9 
Mean Diastolic Blood Pressure (mm 
Hg) 67 ± 8.9 64.2 ± 10.9 
Systolic Pulmonary Artery Pressure 
(mm Hg) 52.7 ± 17.2 47.6 ± 15.7 
Diastolic Pulmonary Artery Pressure 
(mm Hg) 28.1 ±9.3 27.7 ± 9.3 
 
 
 
 
 
 
 
 
 
 
 
 APPENDIX C 
Table 3:  GRADE Table 
 
Comparison Outcome 
Quantity and 
type of 
evidence 
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Decrease GRADE Increase GRADE 
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Efficacy of the 
HeartWare 
Ventricular 
Assist System 
in bridging 
adult heart 
failure patients 
to 
transplantation 
Survival 
to 
transplant 
2 cohort 
(observational) 
High 
survival Low 0 0 0 0 0 +1 0 0 Moderate 
Moderate Survival 
180 days 
on device 
2 cohort 
(observational) 
High 
survival Low 0 0 0 0 0 +1 0 0 Moderate 
 
